Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn:
“At EuroPCR 2026, we are presenting our results:
‘Selecting high-bleeding risk AMI patients with AF for triple antithrombotic therapy after PCI‘
Contemporary antithrombotic management in AF-PCI patients has progressively shifted toward treatment de-escalation, largely driven by concerns surrounding bleeding.
Yet the prevailing paradigm that all high bleeding risk (HBR) patients should uniformly receive abbreviated or simplified regimens deserves reconsideration.
In our cohort of AF patients presenting with STEMI and NSTEMI undergoing PCI, integration of the REDUAL-PCI score with the ARC-HBR trade-off model identified a clinically relevant subgroup in whom ischemic risk remained predominant despite clear HBR features.
Key observations:
- More than 70% of patients demonstrated a REDUAL-PCI score ≥5
- These patients had substantially greater ischemic burden, including prior MI, CKD, and complex PCI
- Ischemic-dominant profiles were threefold more frequent among REDUAL ≥5 patients
- Estimated MI/stent thrombosis risk substantially exceeded bleeding liability in a significant proportion of HBR patients
The important message is straightforward:
High bleeding risk does not necessarily equate to bleeding-risk predominance.
A growing tendency exists to treat HBR as a therapeutic endpoint rather than as one component of a broader competing-risk equation.
Our data suggest this approach may oversimplify decision-making in AF-PCI patients, particularly in those with advanced atherosclerotic and thrombotic substrates.
The combination of REDUAL-PCI and ARC-HBR trade-off assessment may help identify patients in whom ischemic protection remains critically important and in whom triple antithrombotic therapy should not be dismissed reflexively.
The field likely needs to move beyond standardized de-escalation algorithms toward a more nuanced and personalized antithrombotic strategy — one based not solely on bleeding vulnerability, but on the dynamic balance between bleeding and thrombosis.”
Other posts featuring Bartosz Hudzik on Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease